论文部分内容阅读
目的:探讨循环肿瘤细胞(circulating tumor cells,CTC)检测在转移性肾细胞癌临床诊断中的应用价值.方法:2013年3月～2015年5月收治的肾癌患者52例,所有患者在治疗前取外周静脉血标本7.5 ml,用细胞搜索系统(cell search system,CSS)对患者外周血进行CTC定量检测,其中男41例,女11例.结果:CTC检测总体阳性率为48.1％(25/52),存在淋巴结转移及远处转移的患者,其CTC阳性率明显高于无淋巴转移及远处转移的患者,中晚期患者(Ⅲ期+Ⅳ期)其阳性率明显高于早期患者(Ⅰ期+Ⅱ期).结论:CTC检测结果和传统上用来评价肾癌患者的预后的指标其结果一致,CTC的检测可以用来评估肾癌患者的预后,为肾癌患者术后是否应早期进行干预提供依据.“,”Objective:To explore the clinical value of circulating tumor cell (CTC) in patients with metastatic renal cell carcinoma.Method:From March 2013 to May 2015,52 cases with renal ceil carcinoma were treated in our hospital,and 7.5 ml blood was drawn from these patients.CTC were detected by cell search system (CSS) in peripheral blood.Result:The total positive rate was 48.1％ (25/52) among them.The positive rate of CTC with the patients with lymph node metastasis and distant metastasis were significantly higher than those without lymph node metastasis and distant metastasis of patients.The positive rate in patients with advanced (stage Ⅲ + Ⅳ)stage was significantly higher than that in patients with early stage (stage Ⅰ + Ⅱ).Conclusion:CTC detection results are consistent with traditional prognosis indicators.CTC detection may be used to evaluate the prognosis of patients with renal cell carcinoma,and to provide evidence for early intervention.